Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2010. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding the vesting of awards under the 2007 Share Value Plan and subsequent share sales.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Share Sale Price: £12.03 per Ordinary share.
- Transaction Date: February 22, 2010.
Material Changes
The filing details the conclusion of the three-year vesting period for Share Value Plan awards made in 2007, which ended on December 31, 2009. Following vesting, specific PDMRs sold a portion of their shares on February 22, 2010. No material changes to the company's overall financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of executive share plan vesting and trading activity.
Important Facts for Investors
- Executive Share Sales: Four PDMRs (Mr. S M Bicknell, Mr. E J Gray, Mr. D S Redfern, Ms. C Thomas) sold shares immediately following vesting.
- Retention Ratios: Executives retained approximately 59% of vested shares (e.g., Mr. Bicknell retained 1,486 of 2,520 vested shares).
- Transaction Price: Shares were sold at £12.03, which may serve as a reference point for market valuation on the transaction date.
- Scope Limitation: This filing does not contain financial performance data; investors should refer to Form 20-F or quarterly reports for financial results.